About ritlecitinib
Janus kinase 3 and TEC-family kinase inhibitor
Used for
- Treats severe alopecia areata in adults and adolescents aged 12 years and older.
Usual adult dose
50 mg by mouth once daily.
Usual dose in children
For ages 12 years and older: 50 mg by mouth once daily.
Common side effects
- Headache
- Diarrhea
- Acne
- Herpes zoster or other infections
Important warnings
- Can cause serious infections; screening for tuberculosis is recommended before treatment.
- May increase risks of cancer, major cardiovascular events, blood clots, and death.
- Avoid live vaccines during treatment.
- Blood tests may be needed to monitor blood counts and liver enzymes.
Pregnancy
Limited human data; may harm an unborn baby. Avoid use during pregnancy; report pregnancy to a healthcare professional.
Breastfeeding
It is unknown whether ritlecitinib passes into breast milk. Breastfeeding is not recommended during treatment and for 14 hours after the last dose.
Interactions
- Strong CYP3A inhibitors can increase ritlecitinib exposure.
- Strong CYP3A inducers can reduce ritlecitinib effectiveness.
- Other potent immunosuppressants may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.